Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825 [2]

Blood

Volumn 107, Issue 11, 2006, Pages 4571-4572

  Abruzzese, Elisabetta ^a   Del Poeta, Giovanni ^b   Barbato, Rosanna ^b   Fratoni, Stefano ^b   Trawinska, Malgorzata M ^b   Zangrilli, Daniela ^b   Coletta, Angela M ^b   Patroi, Ivona M ^b   Francesconi, Francesca ^b   Santeusanio, Giuseppe ^b   De Fabritiis, Paolo ^b   Amadori, Sergio ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGED; CASE REPORT; CLINICAL FEATURE; HISTOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; MALE; PRIORITY JOURNAL; REMISSION; SKIN DEFECT; TREATMENT OUTCOME;

EID: 33744493963     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-11-4707     Document Type: Letter

References (10)

1. Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy [letter]. Science. 2001;293:2163.
2. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004:64:672-677.
3. Shah N, Nicoll J, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI-571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;289:1938;1942.
4. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol, 2005;23:4100-4109.
5. Brugess MR, Skaggs BJ, Shah NP, et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A. 2005;102:3395-3400.
6. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505.
7. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658-6661.
8. Shah NP, Tran C, Lee FY, at al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.
9. Abruzzese E, Cantonetti M, Morino L, et al. CNS and cutaneous involvement in patients with CML treated with Imatinib in hematologic complete remission: 2 case reports. J Clin Oncol. 2003;21:4256-4258.
10. Breccia M, Nanni M, Mancini F, Russo E, Mecarocci S, Alimena G. Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. Haematologica. 2004;89:ECR11.